Journal of neuroimmunology · 2026
Real-world risks of neurotoxicity with immune checkpoint inhibitors compared with standard chemotherapy.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balshi Alexandra, Dempsey John P, Zhang-James Yanli, Manzano Giovanna S
Аннотация
BACKGROUND: Although reports of immune checkpoint inhibitor-related neurotoxicity are mounting, the relative risks of neurologic complications compared with conventional chemotherapy (also associated with neurotoxicity) remain poorly defined.
OBJECTIVE: To conduct a large, multicenter, real-world cohort study comparing neurologic adverse events among those treated with immune checkpoint inhibitors (ICIs) versus conventional (platinum-based) chemotherapy.
METHODS: We utilized data from the TriNetX research network from 2011 to 2026. We propensity-score 1:1 matched people with cancer who initiated an ICI versus conventional chemotherapy by cancer type along with age, sex, race, ethnicity, body mass index, tobacco use, and other comorbidities. Matched cohorts (n = 46,909 per cohort) were compared using risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: ICIs were associated with significantly greater risks of demyelinating disease (RR 1.42, 95% CI 1.05-1.84), neuromuscular junction disorders (RR 1.43, 95% CI 1.24-1.65), aseptic meningitis (RR 1.61, 95% CI 1.28-2.02), myopathy (RR 1.52, 95% CI 1.27-1.82), Guillain-Barré syndrome (RR 1.87, 95% CI 1.14-3.08), and radiculopathy (RR 1.14, 95% CI 1.06-1.24) compared with conventional chemotherapy. The risks of myelitis (RR 1.50 95% CI 0.85-2.64) and dysautonomia (RR 0.85, 95% CI 0.71-1.01) were equivocal, while chemotherapy was associated with greater risks of neuropathy (RR 0.46, 95% CI 0.44-0.48).
CONCLUSION: In this large, multicenter, real-world cohort study, increased risks of central nervous system, neuromuscular junction, and myopathic toxicities, albeit rare overall, were observed in people with malignancy treated with ICI in comparison to conventional chemotherapy.
OBJECTIVE: To conduct a large, multicenter, real-world cohort study comparing neurologic adverse events among those treated with immune checkpoint inhibitors (ICIs) versus conventional (platinum-based) chemotherapy.
METHODS: We utilized data from the TriNetX research network from 2011 to 2026. We propensity-score 1:1 matched people with cancer who initiated an ICI versus conventional chemotherapy by cancer type along with age, sex, race, ethnicity, body mass index, tobacco use, and other comorbidities. Matched cohorts (n = 46,909 per cohort) were compared using risk ratios (RRs) with 95% confidence intervals (CIs).
RESULTS: ICIs were associated with significantly greater risks of demyelinating disease (RR 1.42, 95% CI 1.05-1.84), neuromuscular junction disorders (RR 1.43, 95% CI 1.24-1.65), aseptic meningitis (RR 1.61, 95% CI 1.28-2.02), myopathy (RR 1.52, 95% CI 1.27-1.82), Guillain-Barré syndrome (RR 1.87, 95% CI 1.14-3.08), and radiculopathy (RR 1.14, 95% CI 1.06-1.24) compared with conventional chemotherapy. The risks of myelitis (RR 1.50 95% CI 0.85-2.64) and dysautonomia (RR 0.85, 95% CI 0.71-1.01) were equivocal, while chemotherapy was associated with greater risks of neuropathy (RR 0.46, 95% CI 0.44-0.48).
CONCLUSION: In this large, multicenter, real-world cohort study, increased risks of central nervous system, neuromuscular junction, and myopathic toxicities, albeit rare overall, were observed in people with malignancy treated with ICI in comparison to conventional chemotherapy.